Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
Three peer-reviewed Signatera head and neck papers: 95.2% sensitivity, detection ~4.3 months before imaging, 100% HPV+ sensitivity. Plus members following NTRA get this by push and email at 07:00:08 ET - it reached us 8.1 seconds after publication. Written by Quantisnow AI from this release. Not…